SOX2 and head and neck squamous cell carcinoma: Further refinement revealed caveolin-1 and Sox-2 protein measurements to retain high predictive accuracy for cetuximab response prediction, which we confirmed in patient samples using immunohistochemistry of a TMA from cetuximab-treated patients with HNSCC with known clinical responses.